Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.
By M. J. Leckie, A. Brinke, Jamey Khan, Z. Diamant, B. O'connor, Christine M Walls, A. Mathur, Hugh C. Cowley, K. Chung, R. Djukanović and 4 more. The Lancet, 2000
1,909 citations recorded by the source corpus.
Subfields: Physiology, Sociology and Political Science, Surgery
View Paper: https://www.semanticscholar.org/paper/16d52a2fd538e7221dda2a07cf3b2e5d2de930a9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
In Sociology and Political Science
In Surgery
Citations in the corpus
- Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. (2003, background): “However, although anti–IL-5 almost totally ablated eosinophils in the blood and sputum (28), tissue eosinophils were reduced rather than depleted (30), possibly as a result of downregulated IL-5Rα expression of airway eosinophils (31, 32).”
- Eosinophils: Biological Properties and Role in Health and Disease (2008, background): “The temporal association between increased inflammatory cell infiltration and increased AHR at 24 hours after allergen challenge in dual responders (Brusasco et al. 1990; Flood-Page et al. 2003b; Dorman et al. 2004a) has led to the suggestion of a causal relationship between the two.”
- Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (2007, neutral): “However, the role and contribution of eosinophils to asthma is undergoing a reevaluation based on studies with an anti-IL-5 treatment that has significantly reduced eosinophils but did not affect asthma control (Leckie et al. 2000).”